Q4 Earnings Forecast for CRVS Issued By HC Wainwright

Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) – Analysts at HC Wainwright issued their Q4 2024 earnings per share (EPS) estimates for Corvus Pharmaceuticals in a report issued on Thursday, January 2nd. HC Wainwright analyst S. Lee expects that the company will post earnings of ($0.12) per share for the quarter. HC Wainwright has a “Buy” rating and a $11.00 price target on the stock. The consensus estimate for Corvus Pharmaceuticals’ current full-year earnings is ($0.68) per share. HC Wainwright also issued estimates for Corvus Pharmaceuticals’ FY2029 earnings at $0.49 EPS.

Other research analysts also recently issued reports about the stock. StockNews.com downgraded shares of Corvus Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Thursday, October 31st. LADENBURG THALM/SH SH boosted their price target on shares of Corvus Pharmaceuticals from $12.00 to $21.00 and gave the company a “buy” rating in a report on Monday, September 16th. Oppenheimer increased their price objective on Corvus Pharmaceuticals from $8.00 to $14.00 and gave the stock an “outperform” rating in a report on Wednesday, November 13th. Finally, Mizuho upgraded Corvus Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, October 22nd. One research analyst has rated the stock with a sell rating, four have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $12.38.

Corvus Pharmaceuticals Price Performance

NASDAQ:CRVS opened at $5.83 on Friday. The stock’s 50-day moving average is $7.67 and its two-hundred day moving average is $5.29. The stock has a market cap of $374.62 million, a PE ratio of -6.27 and a beta of 1.05. Corvus Pharmaceuticals has a fifty-two week low of $1.30 and a fifty-two week high of $10.00.

Institutional Investors Weigh In On Corvus Pharmaceuticals

A number of large investors have recently bought and sold shares of the business. Samlyn Capital LLC grew its stake in shares of Corvus Pharmaceuticals by 160.7% during the second quarter. Samlyn Capital LLC now owns 6,123,021 shares of the company’s stock valued at $11,144,000 after purchasing an additional 3,774,658 shares during the last quarter. Point72 Asset Management L.P. acquired a new position in Corvus Pharmaceuticals during the 2nd quarter worth $10,855,000. Geode Capital Management LLC boosted its position in Corvus Pharmaceuticals by 22.4% in the 3rd quarter. Geode Capital Management LLC now owns 563,009 shares of the company’s stock valued at $2,974,000 after buying an additional 102,869 shares during the last quarter. State Street Corp increased its stake in shares of Corvus Pharmaceuticals by 48.2% in the 3rd quarter. State Street Corp now owns 178,246 shares of the company’s stock valued at $941,000 after buying an additional 57,943 shares during the period. Finally, Connor Clark & Lunn Investment Management Ltd. raised its position in shares of Corvus Pharmaceuticals by 64.7% during the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 137,031 shares of the company’s stock worth $724,000 after acquiring an additional 53,809 shares during the last quarter. 46.64% of the stock is currently owned by institutional investors.

Corvus Pharmaceuticals Company Profile

Corvus Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, focuses on the development and commercialization of immune modulator product candidates to treat solid cancers, T cell lymphomas, autoimmune, allergic, and infectious diseases. Its lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell lymphoma, solid tumors, and atopic dermatitis.